714 assets in Colorectal Cancer

Therapeutic assets addressing Colorectal Cancer, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Ataluren Colorectal Cancer	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)	P1/2	CC (40)
azd8853 Colorectal Cancer	AstraZeneca	P1/2	CC (40)
Bold-100 Colorectal Cancer	Bold Therapeutics, Inc.	P1/2	CC (40)
Camizestrant Colorectal Cancer	AstraZeneca	P1/2	CC (40)
Carbon Nanoparticle-Loaded Iron Colorectal Cancer	Sichuan Enray Pharmaceutical Sciences Company	P1/2	CC (40)
Chm-2101 Car-T Cells Colorectal Cancer	Chimeric Therapeutics	P1/2	CC (40)
ct3001 Colorectal Cancer	Crossignal Therapeutics, Inc.	P1/2	CC (40)
Dabigatran Etexilate Colorectal Cancer	Hutchmed	P1	CC (40)
Darovasertib Colorectal Cancer	IDEAYA Biosciences	P1/2	CC (40)
D-Isoascorbic Acid Colorectal Cancer	Nazarbayev University	P1/2	CC (40)
Eb-Duo-Car-Nk-Cea/Gcc Colorectal Cancer	Beijing Biotech	P1/2	CC (40)
Ebnk-001 Colorectal Cancer	Essen Biotech	P1/2	CC (40)
Etx-19477 Colorectal Cancer	858 Therapeutics, Inc.	P1/2	CC (40)
Fmc-376 Colorectal Cancer	Frontier Medicines Corporation	P1/2	CC (40)
Fog-001 Colorectal Cancer	Parabilis Medicines, Inc.	P1/2	CC (40)
Fosifloxuridine Nafalbenamide Colorectal Cancer	NuCana plc	P2	CC (40)
gm103 Colorectal Cancer	GeneMedicine Co., Ltd.	P1/2	CC (40)
Immunoglobulin G1-Kappa, Anti-[Homo Sapiens Klrb1 (Killer Cell Lectin Like Receptor B1, Nkr-P1A, Natural Killer Cell Surface Protein P1A, Clec5B, Cd161)], Homo Sapiens Monoclonal Antibody; Gamma1 Heavy Chain Homo Sapiens (1-450) [Vh (Homo Sapiens Ighv3-2301 (96.9%) -(Ighd) -Ighj401 (85.7%), Q120>R (113), Cdr-Imgt [8.8.14] (26-33.51-58.97-110)) (1-121) -Homo Sapiens Ighg101, G1M17,1 Ch1 K120, Ch3 D12, L14, G1V29 Ch2 A84.4 (Ch1 K120 (218) (122-219), Hinge 1-15 (220-234), Ch2 G1V29 Ch2 N84.4>A (301) (235-344), Ch3 D12 (360), L14 (362) (345-449), Chs K2>Del (450)) (122-450)], (224-214')-Disulfide With Kappa Light Chain Homo Sapiens (1'-214') [V-Kappa (Homo Sapiens Igkv1-1201 (94.7%) -Igkj401 (91.7%), Cdr-Imgt [6.3.9] (27'-32'.50'-52'.89'-97')) (1'-107') -Homo Sapiens Igkc01 (100%), Km3, A45.1 (153'), V101 (191') (108'-214')]; Dimer (230-230'':233-233'')-Bisdisulfide, Produced In Chinese Hamster Ovary (Cho) Cells, Cell Line Cho-K1 Lacking The Glutamine Synthetase (Gs-Ko) Gene, Non-Glycosylated Colorectal Cancer	Immunitas Therapeutics	P1/2	CC (40)
Immunoglobulin G1-Kappa, Anti-[Homo Sapiens Met (Met Proto-Oncogene, Hepatocyte Growth Factor (Hgf) Receptor, Hgfr, Scatter Factor (Sf) Receptor, Hgf/Sf Receptor, Receptor Tyrosine-Protein Kinase C-Met, Papillary Renal Cell Carcinoma 2, Rccp2)] And Anti-[Homo Sapiens Egfr (Epidermal Growth Factor Receptor, Receptor Tyrosine-Protein Kinase Erbb-1, Erbb1, Her1, Her-1, Erbb)], Homo Sapiens Monoclonal Antibody, Bispecific Colorectal Cancer	Betta Pharmaceuticals Co., Ltd.	P1/2	CC (40)
Interleukin-15 Colorectal Cancer	Essen Biotech	P1/2	CC (40)
ipn01194 Colorectal Cancer	Ipsen	P1/2	CC (40)
jk08 Colorectal Cancer	Salubris Biotherapeutics Inc	P1/2	CC (40)
Kras Neoantigen Nanovaccine Colorectal Cancer	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School	P1/2	CC (40)
lyl273 Colorectal Cancer	Lyell Immunopharma, Inc.	P1/2	CC (40)
neo212 Colorectal Cancer	Neonc Technologies, Inc.	P1/2	CC (40)
Neoantigen Specific Tcr-T Cell Drug Product Colorectal Cancer	Alaunos Therapeutics	P1/2	CC (40)
Opnurasib Colorectal Cancer	Novartis Pharmaceuticals	P1/2	CC (40)
Petosemtamab Colorectal Cancer	Merus B.V.	P1/2	CC (40)
Pimasertib Colorectal Cancer	Day One Biopharmaceuticals, Inc.	P1/2	CC (40)
Pttl Colorectal Cancer	Neogap Therapeutics AB	P1/2	CC (40)
Revumenib Colorectal Cancer	Syndax Pharmaceuticals	P1/2	CC (40)
Rezatapopt Colorectal Cancer	PMV Pharmaceuticals, Inc	P1/2	CC (40)
rp-001 Colorectal Cancer	Recurv Pharma Inc	P1/2	CC (40)
s241656 Colorectal Cancer	Institut de Recherches Internationales Servier	P1/2	CC (40)
Sacituzumab Tirumotecan Colorectal Cancer	Merck Sharp & Dohme LLC	P1/2	CC (40)
Saruparib Colorectal Cancer	AstraZeneca	P1/2	CC (40)
Sitagliptin Colorectal Cancer	Second Affiliated Hospital, School of Medicine, Zhejiang University	P1/2	CC (40)
SL-28 Colorectal Cancer	Second Life Therapeutics	P1/2	CC (40)
tb511 Colorectal Cancer	Twinpig Biolab, Inc.	P1/2	CC (40)
tc-510 Colorectal Cancer	TCR2 Therapeutics	P1/2	CC (40)
Testosterone Undecylate Colorectal Cancer	Aminex Therapeutics, Inc.	P1/2	CC (40)
TQB2930 for injection Colorectal Cancer	Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.	P1/2	CC (40)
tt-4 Colorectal Cancer	Portage Biotech	P1/2	CC (40)
tu2218 Colorectal Cancer	TiumBio Co., Ltd.	P1/2	CC (40)
vb15010 Colorectal Cancer	Zhejiang Yangli Pharmaceutical Technology Co., Ltd.	P1/2	CC (40)
Vofatamab Colorectal Cancer	Fusion Pharmaceuticals Inc.	P1/2	CC (40)
XP-102 Colorectal Cancer	Xynomic Pharmaceuticals, Inc.	P1/2	CC (40)
XS-03 Colorectal Cancer	NovaOnco Therapeutics Co., Ltd.	P1/2	CC (40)
XYA02 Colorectal Cancer	XYone Therapeutics, Inc	P1/2	CC (40)
Zirconium Zr 89 Crefmirlimab Berdoxam Colorectal Cancer	AstraZeneca	P1/2	CC (40)

Showing 451 to 500 of 714 assets

PreviousPage 10 of 15Next